GVHD prevention: an ounce is better than a pound
- PMID: 22226102
- PMCID: PMC3573530
- DOI: 10.1016/j.bbmt.2011.10.034
GVHD prevention: an ounce is better than a pound
Similar articles
-
Acute graft-versus-host disease does not require alloantigen expression on host epithelium.Nat Med. 2002 Jun;8(6):575-81. doi: 10.1038/nm0602-575. Nat Med. 2002. PMID: 12042807
-
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.Nat Med. 2005 Nov;11(11):1244-9. doi: 10.1038/nm1309. Epub 2005 Oct 16. Nat Med. 2005. PMID: 16227991
-
[Preventive measures for graft-versus-host disease].Nihon Naika Gakkai Zasshi. 2005 Jul 10;94(7):1356-61. doi: 10.2169/naika.94.1356. Nihon Naika Gakkai Zasshi. 2005. PMID: 16097592 Review. Japanese. No abstract available.
-
Biology of graft-versus-host responses: recent insights.Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S10-4. doi: 10.1016/j.bbmt.2012.11.005. Biol Blood Marrow Transplant. 2013. PMID: 23290438 Free PMC article. Review. No abstract available.
-
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.J Exp Med. 2011 May 9;208(5):1069-82. doi: 10.1084/jem.20101709. Epub 2011 May 2. J Exp Med. 2011. PMID: 21536742 Free PMC article.
Cited by
-
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.J Hematol Oncol. 2013 Feb 8;6:15. doi: 10.1186/1756-8722-6-15. J Hematol Oncol. 2013. PMID: 23394705 Free PMC article. Clinical Trial.
-
Mouse models in bone marrow transplantation and adoptive cellular therapy.Semin Hematol. 2013 Apr;50(2):131-44. doi: 10.1053/j.seminhematol.2013.03.026. Epub 2013 Jun 11. Semin Hematol. 2013. PMID: 24216170 Free PMC article. Review.
-
Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.PLoS One. 2016 Dec 12;11(12):e0167997. doi: 10.1371/journal.pone.0167997. eCollection 2016. PLoS One. 2016. PMID: 27942010 Free PMC article.
-
Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.Handb Exp Pharmacol. 2022;272:209-243. doi: 10.1007/164_2021_544. Handb Exp Pharmacol. 2022. PMID: 34628553 Free PMC article.
References
-
- Petersdorf EW, Malkki M. Genetics of risk factors for graft-versus-host disease. Semin Hematol. 2006;43:11–23. - PubMed
-
- Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923–1930. - PubMed
-
- Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371–380. - PubMed
-
- Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003;3:371–382. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources